B·R·A·H·M·S Clinical Solutions: Aneuploidy and Neural Tube Defect Screening

Discover the power of prenatal screening on KRYPTOR for your patients

As a trusted obstetrician/gynecologist, you understand the importance of accurate and reliable prenatal screening. That's why we are proud to introduce our complete solution, combining the power of Thermo Scientific B·R·A·H·M·S Biomarkers, Thermo Scientific B·R·A·H·M·S KRYPTOR instruments, and Thermo Scientific B·R·A·H·M·S Fast Screen Software. With over 25 years of expertise in the field, we are committed to providing you with the tools and support you need to make confident clinical decisions.

 

Complete biomarker portfolio for trisomy screening:

Our solution provides a complete biomarker portfolio for trisomy and neural tube defect screening. With a wide range of assays tailored to specific needs, you can confidently assess risk and make informed clinical decisions.

 

Our B·R·A·H·M·S Biomarkers offer a wide range of options to cover screening strategies throughout pregnancy. With our solution, you have the flexibility to choose the most suitable biomarkers for your specific screening needs for the best clinical performance.

 

Combined screening in first trimester, as described below:1

 

When ultrasound is not available, the quadruple test in first trimester can be proposed, as described below:2

 

In second trimester, with no need of ultrasound, biomarkers can be combined to provide an efficient risk assessment, as described below:5

 

Trust your results with clinically validated assays.

 

All the intended uses covered by our assays have been clinically validated ensuring the highest clinical performance and are fully compliant with the IVDR.

First trimester trisomy screening:

 

Intended use
Risk assessment for Trisomy 21 Trisomy 18 Trisomy 13 Pre-eclampsia
PAPP-A
Free βhCG  
PIGF    
AFP      

Second trimester trisomy and neural tube defect screening:

 

Intended use
  Risk assessment Diagnosis
  Trisomy 21 Trisomy 18 NTD* in serum and plasma (heparin) NTD* in amniotic fluid
AFP
hCG+β     
Free βhCG    
uE3      
Inhibin A      

* Neural Tube Defect

 

Aneuploidy and neural tube defect screening products do not have FDA clearance for sale in the US.

Reliable results due to good precision and low interference:

 

We understand the importance of accurate results in prenatal screening. Our KRYPTOR Instruments utilize advanced technology to deliver reliable and precise measurements, minimizing interference and ensuring the highest level of confidence in your patients' results. All B·R·A·H·M·S KRYPTOR Prenatal Screening Assays fulfill the strict quality requirements of the Fetal Medicine Foundation (FMF).

Confidence in clinical decisions:

Thermo Fisher Scientific boasts over 20 years of market presence and expertise in prenatal screening concepts, making it the preferred partner of hundreds of screening laboratories worldwide. More than 170 studies have been performed on B·R·A·H·M·S KRYPTOR Analyzers to establish and improve prenatal screening.

 

With our complete solution, you can have full confidence in your clinical decisions. Our validated assays, state-of-the-art instruments, and intuitive software work seamlessly together, providing you with accurate data and actionable insights to guide your patient's care.

 

Expertise:

Benefit from our 25 years of expertise in the field of prenatal screening. We have a deep understanding of the complexities involved and have continuously evolved our solutions to meet changing needs. Partner with us to leverage our experience and stay at the forefront of prenatal care.

 

Educational support:

We believe in equipping clinicians with the knowledge and resources to excel in their practice. Our educational support includes literature reviews, videos, and access to a network of experts. We are committed to your professional success.

Maximizing screening benefits: The power of contingent screening

To achieve the best possible performance in prenatal screening, the Fetal Medicine Foundation UK and expert clinicians strongly advocate for the adoption of a contingent screening approach.3

Get more with contingent screening:

 

Identify more fetal defects

Contingent screening includes ultrasound, allowing for the identification of structural abnormalities that may impact fetal health4. 

 

Identify maternal complications

Biomarkers such as PlGF, however, play a crucial role in identifying severe maternal complications such as pre-eclampsia, enabling timely interventions and improved maternal care.4

 

With contingent screening, clinicians and laboratory managers can provide patients with more accurate risk assessments and personalized care plans, ultimately leading to improved outcomes for both mothers and babies.

Review the clinical evidence with B·R·A·H·M·S KRYPTOR assays

Trisomy screening with B·R·A·H·M·S assays has been in routine use since 1999. Hundreds of publications show the clinical performance of our B·R·A·H·M·S Prenatal Screening solution.

 

Robust risk calculation: high quality algorithms

B·R·A·H·M·S Fast Screen pre I plus Software offers first trimester algorithms that are based on the FMF data and are updated to reflect recently published improvements. This huge database ensures a statistically significant robustness.6

Customer story

Resources

References

1.     Kagan et al. Human reproduction 2008 ;23(9):1968-1975

2.     Caron L et al. Clin Chem Lab Med 2023 ;61(9) :1630-1635

3.     Nicolaides et al. Ultrasound Obstet Gynecol 2013 ;42 :41-50

4.     Strauss TS et al. The Journal of Maternal-Fetal & Neonatal Medicine 2022; 35:25, 9907-9912

5.     Nicolaides et al. Prenat Diagn 2011 ;31 :7-15

6.     Wright D et al. Ultrasound Obstet Gynecol 2010 ;36(4) :404-411

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

 

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.

 

KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.